News

Pfizer, AstraZeneca back a new strategy for cancer drug R&D

A pair of pharma giants have partnered with a prominent cancer research charity in the U.K. on an innovative new approach to testing targeted oncology therapies, building on the country's national program for tumor testing in a way that may help make it a global center of cancer R&D.

Vital Therapies banks $54M in a downsized IPO retry

After pulling the plug on an $86 million float in biotech's halcyon 2013, Vital Therapies has made its way to Wall Street with a scaled-down $54 million offering, cash it will use to advance its drug-device combo for liver failure.

GlaxoSmithKline and Galapagos succeed in psoriasis after two setbacks

Galapagos and partner GlaxoSmithKline say their anti-inflammation candidate hit its mark in a mid-stage trial on psoriasis, a stroke of good news for a drug beset by developmental slipups.

Biotech upstart grabs $18M to study a new drug to protect pregnancies

A biotech startup with roots in Palo Alto, CA has raised $18 million in venture cash to open up a second mid-stage study of its lead therapy, looking to shape a reputation for itself in the lightly populated R&D world of reproductive medicine.

Which therapies top Thomson Reuters' list of new drugs to watch this year?

The industry analysts at Thomson Reuters put their heads together to tap the biggest new blockbusters in the making this year and surprised no one by capping the list with Gilead's Sovaldi.

Baxter's latest bleeding drug hits the mark in PhIII

Baxter charted another late-stage success in its growing hemophilia franchise, posting positive top-line results for an orphan bleeding disorder treatment.

Have the biotech bears run out of steam?

The Nasdaq biotech index is down more than 20 percent since February, which has caused considerable anguish among the gamblers wooed into the high-risk field as stocks boomed last year. But some analysts are betting that the worst is over and that the correction has run its course.

Column Group nears goal line for $250M biotech venture fund

The Column Group has been a busy venture player in the biotech world. And the VC plans to stay busy. In a recent filing at the FDA, the venture group revealed that it has raised close to $176 million out of a planned $250 million fund.

BioAlliance and Topotarget plan to merge, pooling their cancer pipelines

European biotechs BioAlliance Pharma and Topotarget have signed up to join forces, plotting to merge under the former's name and combine their pipelines of late-stage oncology drugs.

VCs gamble $96M on rare disease drug, biosimilar play and new drug for AMD

Making up for an anemic first quarter, a group of VCs operating on both sides of the Atlantic has triggered a string of new rounds totaling $96 million to back three biotech upstarts.

Boehringer dogged by doubts as it touts a growing PhIII pipeline

Boehringer Ingelheim wants to be considered part of the major league in global drug R&D. And it's been spending some blockbuster cash on a bid to win a big slate of new drug approvals that could eclipse even the biggest rivals.

GlaxoSmithKline wins an FDA nod for its GLP-1 diabetes drug albiglutide

After a three-month delay pushed pause on its commercial plans, GlaxoSmithKline has secured FDA approval for albiglutide, a new diabetes treatment that will contend for market share in a fast-crowding space.

Angion swings for a $36M IPO as biotech's bear turn drags on

Uniondale, NY's Angion Biomedica is eyeing $36 million to bankroll its pipeline of treatments for organ injury, hoping to buck an alarming trend for biotech stocks and trade on the Nasdaq under "ANGN."

Little Lexicon posts positive diabetes data as rival pharma giants race ahead

The newly downsized Texas-based Lexicon Pharmaceuticals says it nailed promising data on its experimental diabetes drug, positioning it for a late-stage study that could leave it poised to compete with a full lineup of rival treatments already brought to the market by a group of pharma giants.

Startup AAVLife sets sights on ataxia with $12M and a novel gene therapy

Parisian biotech AAVLife has come out of stealth with a Versant Ventures-led $12 million A round, looking to advance a gene-deleting therapy that promises to treat the rare and deadly Friedreich's ataxia.

Roche adds a slate of PhIII schizophrenia trial failures to bitopertin's obituary

A few months ago Roche put out the word that its schizophrenia drug bitopertin had flunked the first two Phase III studies in a lengthy lineup of clinical trials. And today the pharma giant almost completed its obituary for a drug program that had been touted as one of Roche's top blockbuster prospects, adding a long slate of trial flops to the record.

Merck bags FDA approval for its grass pollen pill Grastek

Merck picked up an expected FDA approval for the first of three immunotherapies in its allergy pipeline, gearing up to launch a grass pollen-fighting treatment with hopes of cracking a market dominated by injections.

ThromboGenics is picking between billion-dollar bids, report says

Just over a month into its search for "strategic options," ThromboGenics has rounded up a bevy of high-dollar offers that could value the company at as much as $1.3 billion, Bloomberg reports, courted by drugmakers who see promise in its underperforming eye drug.

NeoStem strikes deal to acquire California Stem Cell

NeoStem says it will acquire California Stem Cell and a Phase III-ready cancer immunotherapy.

Novartis slams the brakes on once-ambitious RNAi development efforts

Novartis is shuttering a large part of its once-ambitious RNAi research effort in Boston, FierceBiotech has learned. The pharma giant, which has extensive research operations in the Boston area, confirmed the decision, saying that the lingering problems associated with delivering these therapies tied to the small number of relevant targets they could shoot for drove the move.